Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Several factors can increase the risk of urinary tract infections UTIs but during winter there’s one specific reason that can ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...